Background— A need for integrated headache care using comprehens

Background.— A need for integrated headache care using comprehensive and standardized assessment for diagnosis of headache, psychiatric comorbidity, and burden of disease exists. There are little published data on long-term efficacy of multidisciplinary treatment programs for chronic headache. Design.—

A prospective, observational, 12-month, follow-up study. Subjects and Methods.— Selleckchem LY2157299 Prospectively recruited consecutive patients with frequent difficult-to-treat headaches (n = 201; 63 migraine, 11 tension-type headache, 59 combined migraine/tension-type headache, and 68 medication overuse headache) were enrolled. Outcome measures included prospective headache diaries, a medication survey, Migraine Disability Assessment, 12-item short form health survey, and the Hospital Anxiety and Depression Scale. Results.— The primary outcome of a reduction of ≥50% of headache frequency (days/month) was observed in 62.7%. Mean headache frequency decreased from 14.4 ± 8.2 to 7.6 ± 8.3 days/month, P < .0001. Secondary outcomes improved significantly in the total

cohort and all headache subgroups. Predictors for good outcome were younger age, few days lost at work/school, and familiarity with progressive muscle relaxation therapy at baseline. Conclusions.— The present analysis provided support for a cross-sectional multidisciplinary EMD 1214063 in vitro integrated headache-care program. “
“Background.— Dihydroergotamine (DHE) has been used for decades to treat

migraine, but is currently contraindicated in patients with hemiplegic migraine and basilar-type migraine (BTM). Objective.— To assess the safety of DHE in patients with symptoms of BTM that do not meet criteria for BTM. Methods.— Retrospective 上海皓元 analysis of patients admitted to an outpatient infusion room at a tertiary care center caring for patients with headache disorders. Incidence and types of adverse events as well as pain levels were reviewed and analyzed. Pain was assessed via the visual analog scale (VAS). Results.— Fifty consecutive patient records were reviewed. Mean age was 38.42. All patients met International Classification of Headache Disorders-II (ICHD-II) criteria for migraine and reported 1 posterior fossa symptom as defined by the ICHD-II criteria for BTM. Patients did not necessarily have a posterior fossa symptom in the attack treated. Eighteen percent (9/50) patients had adverse events, and only 3 of these halted DHE infusion. No patients had neurologic or cardiologic events. The mean decrease in pain was 3 points on the VAS (P < .0001).

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>